Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
816 NT-I7 and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that favors anti-tumor efficacy in combination with checkpoint inhibitors
Compose a Response to This Article
Other responses
No responses have been published for this article.
